New MEK inhibitor PAS-004 enters human trials for Hard-to-Treat cancers
NCT ID NCT06299839
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new drug called PAS-004 in people with advanced solid tumors that have certain gene mutations (RAS, NF1, or RAF). The main goal is to see how safe the drug is and what side effects it causes. About 48 participants will take the drug by mouth daily for up to 2 years, with regular check-ups to monitor their health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PAS-004 (a MEK inhibitor)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors that have specific genetic mutations.
What could go wrong
This is an early Phase 1 trial with only 48 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Oncology Bucharest Prof. Dr. Alexandru Trestioreanu
RECRUITINGBucharest, 022328, Romania
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institute of Oncology Prof. Dr. Ion Chiricuta
RECRUITINGCluj-Napoca, RO-400015, Romania
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
MBAL Sveta Sofia
RECRUITINGSofia, 1404, Bulgaria
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology
ACTIVE_NOT_RECRUITINGAustin, Texas, 78758, United States
-
NEXT Oncology
ACTIVE_NOT_RECRUITINGIrving, Texas, 75039, United States
-
NEXT Oncology
ACTIVE_NOT_RECRUITINGSan Antonio, Texas, 78229, United States
-
NEXT Oncology
ACTIVE_NOT_RECRUITINGFairfax, Virginia, 22031, United States